Skip to main content

Lipocine Inc.

corporate_fare Company Profile

Lipocine Inc.

LPCN·NASDAQ·Life Sciences·CIK 0001535955

Lipocine Inc. is a biopharmaceutical company that uses its own technology platform to create new products for delivering molecules orally that were previously difficult to administer. These delivery technologies aim to improve patient compliance and safety by offering oral treatment options. The company's main development programs focus on oral delivery solutions for drugs that are not easily absorbed by the body. Lipocine has a range of distinct product candidates designed to address significant unmet needs in neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation for both men and women. On January 12, 2024, Lipocine entered into a license agreement with Gordon Silver Limited and Verity Pharmaceuticals, Inc. This agreement grants Verity an exclusive, royalty-bearing, and sublicensable right to commercialize TLANDO for testosterone replacement therapy (TRT) in the U.S. and Canada. TLANDO is an oral treatment for TRT in adult males with conditions related to a deficiency or absence of natural testosterone (primary or hypogonadotropic hypogonadism), and it contains testosterone undecanoate (TU). Verity is also responsible for any post-marketing studies required by the United States Food and Drug Administration (FDA). On January 31, 2024, Lipocine's previous license agreement with Antares Pharma, Inc. was terminated. The transfer of U.S. commercial rights for TLANDO from Antares to Verity for its distribution, marketing, and sale was completed on February 1, 2024. The Verity License Agreement also gives Verity a license to develop and commercialize LPCN 1111 (also known as TLANDO XR), which is the company's potential next-generation, once-daily oral product candidate for testosterone replacement therapy, containing testosterone tridecanoate (TT), in the U.S. and Canada.

Lipocine Inc. (NASDAQ:LPCN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 36 items for LPCN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for LPCN spans 4, 10-Q, 8-K, DEFA14A.

Recent high-impact activity:

  • Director Higuchi Buys 150,000 LPCN Shares for $225,225 on the Open Market
  • Lipocine CEO Mahesh Patel Buys 50,000 Shares for $79,488 Open-Market
  • Lipocine Q3 Loss Narrows to $0.7M on $2.3M Revenue; $21.5M Cash Funds Runway to Nov 2027
  • Lipocine Swings to Near-Breakeven as Q3 Revenue Jumps to $2.3M
  • Health Canada Clears Lipocine's TLANDO, Setting Stage for Year-End Launch

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.98M
Net Income
-$9.63M
Diluted EPS
-$1.69
Op. Cash Flow
-$9.76M
Operating Income
-$10.37M
Cash & Equivalents
$5.21M
Debt / Equity
0.00×
Net Margin
-487.1%
Shares Outstanding
6.16M sh
Source: 10-K · filed 2026-03-10 · accession 0001493152-26-009411

Short Interest & Short Volume

1.50 days to cover

FINRA reported short interest of 325,401 shares in LPCN as of the October 30, 2026 settlement, a 7.4% decrease from the prior period — about 1.5 days to cover at its recent average daily volume. On November 20, 2026, 15.0% of LPCN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)325,401 shares as of October 30, 2026
Change vs prior period▼ 7.4%
Days to cover1.50 at avg daily volume of 216,649
Daily short volume (FINRA facilities)15.0% of 44,341 shares on November 20, 2026
5-day average short volume25.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for LPCN, detected from its recent SEC filings.

ATM program

ATM Sales Agent Fee Increased · Existing ATM Program Context

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with L →
$1.53 +3.58% today
52-week range · as of 2026-11-20 $1.36 – $12.37
Market cap
$16.39M
Volume
219.9K (0.9× avg)
3-mo avg 252.2K
Live data · 2026-11-21 08:29 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LPCN - Latest Insights

LPCN
Nov 20, 2026, 5:28 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $1.44
Real-time Price: $1.53 info
Change: +$0.093 (+6%) info
Market Cap: $16.389M info
LPCN
Nov 13, 2026, 3:23 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $1.69
Real-time Price: $1.53 info
Change: -$0.157 (-9%) info
Market Cap: $16.389M info
LPCN
Nov 05, 2026, 9:30 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.53 info
Change: +$0.063 (+4%) info
Market Cap: $16.389M info
LPCN
Nov 05, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.45
Real-time Price: $1.53 info
Change: +$0.083 (+6%) info
Market Cap: $16.389M info
LPCN
Oct 07, 2026, 6:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Updated Oct 7, 11:47 AM ET — Lipocine shares rose 15.72% to $2.43 following the approval.
Price at Filing: $2.16
Real-time Price: $1.53 info
Change: -$0.627 (-29%) info
Market Cap: $16.389M info
LPCN
Sep 14, 2026, 6:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.27
Real-time Price: $1.53 info
Change: -$0.737 (-32%) info
Market Cap: $16.389M info
LPCN
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.13
Real-time Price: $1.53 info
Change: -$0.597 (-28%) info
Market Cap: $16.389M info
LPCN
Aug 04, 2026, 8:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $2.12
Real-time Price: $1.53 info
Change: -$0.587 (-28%) info
Market Cap: $16.389M info
LPCN
Aug 04, 2026, 6:08 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.15
Real-time Price: $1.53 info
Change: -$0.6123 (-29%) info
Market Cap: $16.389M info
LPCN
Aug 04, 2026, 6:03 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.15
Real-time Price: $1.53 info
Change: -$0.6123 (-29%) info
Market Cap: $16.389M info
LPCN
Jun 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.26
Real-time Price: $1.53 info
Change: -$0.727 (-32%) info
Market Cap: $16.389M info
LPCN
Jun 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.21
Real-time Price: $1.53 info
Change: -$0.677 (-31%) info
Market Cap: $16.389M info
LPCN
Jun 04, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.11
Real-time Price: $1.53 info
Change: -$0.577 (-27%) info
Market Cap: $16.389M info
LPCN
May 26, 2026, 5:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.30
Real-time Price: $1.53 info
Change: -$0.767 (-33%) info
Market Cap: $16.389M info
LPCN
May 07, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.35
Real-time Price: $1.53 info
Change: -$0.8183 (-35%) info
Market Cap: $16.389M info
LPCN
May 07, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.36
Real-time Price: $1.53 info
Change: -$0.827 (-35%) info
Market Cap: $16.389M info
LPCN
May 07, 2026, 9:00 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.36
Real-time Price: $1.53 info
Change: -$0.827 (-35%) info
Market Cap: $16.389M info
LPCN
Apr 21, 2026, 5:12 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $2.33
Real-time Price: $1.53 info
Change: -$0.7971 (-34%) info
Market Cap: $16.389M info
LPCN
Apr 21, 2026, 5:01 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $2.33
Real-time Price: $1.53 info
Change: -$0.7971 (-34%) info
Market Cap: $16.389M info
LPCN
Apr 21, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.34
Real-time Price: $1.53 info
Change: -$0.807 (-34%) info
Market Cap: $16.389M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets